# US 2025/0049970 A1 · Dll3 targeting peptides and constructs thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049970 A1
- Document ID: US20250049970A1
- Status: Published application
- Kind: A1
- Application number: 18/743,028
- Filed: 2024-06-13
- Published: 2025-02-13
- Earliest claimed: 2023-06-14
- Assignees: Mariana Oncology Inc.
- Applicants: Mariana Oncology Inc.
- Inventors: Chester A. METCALF, III; Chunhui Huang; Murray Wan; Thomas C. Bruton; Zhong Ma; Lihua Wu; Roberto Costante; Danila Branca; Alonso Ricardo
- Web page: https://patentgrep.com/patent/US20250049970A1

## CPC

- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K 14/001: {by chemical synthesis}
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 2121/00: Preparations for use in therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

## Claims

### Claim 1

A cyclic peptide of Formula C:
or a pharmaceutically acceptable salt thereof,
wherein:
P1 is selected from: H, -L1-Chelator,
D1 is selected from H, CH3, C(O)OH, and —NR″-Chelator;
L1 is absent or selected from
wherein the amino group of L1 connects to the carbonyl group of P1 or Chelator to form an amide bond;
P2 is selected from C(O)NH2, C(O)OH, CH2OH, -L2-Chelator,
D2 is OH or NH2;
L2 is absent or selected from:
wherein the amino group of L2 connects to the carbonyl group of P2 or Chelator to form an amide bond;
P3 is selected from H, Ac, -L3-Chelator,
L3 is absent or independently selected from
wherein the carbonyl group of L3 connects to an amine group of P2 to form an amide bond;
D3 is independently selected from: CH3, C(O)OH, —NR″-Chelator, and
X is halogen;
R0 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid;
R1 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid;
R2 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid;
R3 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid;
B1 is C1-6 alkylene;
C1 is C1-6 alkylene;
A1 is selected from:
wherein w is selected from 1, 2, or 3;
R4 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid, both of which are optionally substituted with Chelator, CH2C(O)OH, or C(O)(CH2CH2O)p(CH2)2N(CH3)3+, wherein the Chelator is optionally substituted to the amino acid side chain through a Linker;
R5 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid, both of which are optionally substituted with Chelator, wherein the Chelator is optionally substituted to the amino acid side chain through a Linker;
R6 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid;
R7 is selected from:
(i) an amino acid side chain of a natural amino acid,
(ii) an amino acid side chain of an unnatural amino acid, or
(iii) selected from the group consisting of:
wherein L4 is absent or independently selected from:
wherein the carbonyl group of L4 connects to an amine group of R7 to form an amide bond;
R8 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid;
R9 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid;
R10 is an amino acid side chain of a natural amino acid or an amino acid side chain of an unnatural amino acid;
m is 0 or 1;
each n, q, and u are independently an integer from 0 to 16;
each p is independently an integer from 0 to 24;
each s is independently an integer from 0 to 16;
each t is independently 1, 2, 3, 4, 5, or 6;
each R′ is independently selected from H, C(O)OH, (CH2)OH, and NHAc; and
each R″ is independently selected from H and CH3;
wherein either the cyclic peptide does not comprise a Chelator, or at least one of R4, R5, or R7 is substituted with a Chelator or Chelator-containing group;
each alpha-carbon atom on the peptide backbone is optionally substituted with methyl;
when a variable group R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, or R10 is the amino acid side chain of a cyclic amino acid, the corresponding amino acid nitrogen of the peptide backbone of Formula C forms part of the cyclic group; and
wherein the cyclic peptide optionally comprises a radionuclide.

### Claim 2 (depends on 1)

The cyclic peptide of claim 1, wherein the cyclic peptide of Formula C is a cyclic peptide of Formula Ci, Formula Cii, or Formula Ciii:
or a pharmaceutically acceptable salt thereof.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein P1 is Ac or CH3(OCH2CH2)8-16C(O).

### Claim at position 5

6-7. (canceled)

### Claim 8 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein P2 is selected from C(O)NH2, C(O)OH, and

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The cyclic peptide of claim 1, wherein the cyclic peptide of Formula C is a cyclic peptide of Formula Civ:
or a pharmaceutically acceptable salt thereof
wherein each R is, independently for each occurrence, selected from H, CH3, OH, halogen, C(O)OH, and N(R″)2.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein R7 is selected from the group consisting of
wherein L4 is absent or independently selected from:

### Claim 13 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein
m is 0;
P1 is selected from H, Ac,
wherein:
n and s are each independently 9, 10, 11, 12, or 13;
P2 is selected from C(O)NH2, C(O)OH,
P3 is Ac or
X is halo;
D1 is CH3 or C(O)OH;
R1 is selected from the group consisting of an amino acid side chain of Trp, 2Nal, 1Nal, 4CF3-Phe, 7Aza-Trp, 1Me-Trp, 50H-Trp, BIP, 5OMe-Trp, 4F-Phe, 3Pya, 4Pya, PAF, MAF, OAF, 5Qui, 7MeO-Trp, 7Me-Trp, 5F-Trp, 7Cl-Trp, D-Ala, Ala, alpha-Me-Trp, and NMe-Trp;
R2 is selected from the group consisting of an amino acid side chain of Thr, D-Ala, Ala, alpha-Me-Thr, Lys, and NMe-Thr;
R3 is selected from the group consisting of an amino acid side chain of Ile, Env, CHA, CBA, Nle, Tbg, THPG, Chg, 2Nal, 1Nal, 2CF3-Phe, 2PhEt-Ala, D-Ala, Ala, Leu, t-Bu-Ala, NMe-Nle, α-tert-amylGly, Allo-Ile, Lys(C12), Lys(C14), Lys(C16), alpha-Me-Ile, and NMe-tBuAla;
A1 is selected from the group consisting of:
R4 is selected from the group consisting of an amino acid side chain of Asn, D-Ala, Ala, DAB-4-NHCOC5H11, DAB-4-NHCOC7h15, Asp, Ser, Lys(DOTA), Lys, 3-(4-piperidinyl)-Ala, 3-(1-morpholinyl)-Ala, 3Pya, 4Pya, Glu, NMe-Asn, PipA(acetic), Pip(PegNMe3)Ala, and Pip(GAE-DOTA)Ala;
R5 is selected from the group consisting of an amino acid side chain of Asn, Ala, D-Ala, Trp, Asp, Lys, Lys(DOTA), 3Pya, 4Pya, 3-(4-piperidinyl)-Ala, 3-(1-morpholinyl)-Ala, Glu, NMe-Asn, and Ser;
R6 is selected from the group consisting of an amino acid side chain of Trp, 4CF3-Phe, 1Me-Trp, 7Aza-Trp, BIP, 2Nal, 1Nal, alpha-Me-Trp, D-Ala, Ala, 4F-Phe, 5F-Trp, 5MeO-Trp, Asn, 50H-Trp, 7Me-Trp, 7MeO-Trp, 7Cl-Trp, and NMe-Trp;
R7 is:
(i) selected from the group consisting of an amino acid side chain of 3Pya, 4Pya, Lys(Me)3, His, Ala, D-Ala, Gln, Lys, Glu, Arg, Orn, NMe-His, and Ser; or
(ii) selected from the group consisting of:
each s is independently 3, 5, 10, 12, or 14;
R3 is selected from the group consisting of an amino acid side chain of Asp, D-Ala, Ala, Asn, Thr, NMe-Asp, and alpha-Me-Asp;
R9 is selected from the group consisting of an amino acid side chain of Trp, 7Aza-Trp, 1Me-Trp, D-Ala, Ala, 4F-Phe, 1Nal, 2Nal, 5F-Trp, 5MeO-Trp, alpha-Me-Trp, 7Cl-Trp, 50H-Trp, 7Me-Trp, 7MeO-Trp, and NMe-Trp; and
R10 is selected from the group consisting of an amino acid side chain of Pro, D-Ala, Ala, alpha-Me-Pro, trans4Fluoro-Pro, cis4Fluoro-Pro, trans40H-Pro, cis40H-Pro, Pip, 5,5-diMe-Pro, NMe-Ser, trans4NH2-Pro, cis4NH2-Pro, Sar, Aze, NMe-Ala, NMe-Leu, R-3Me-Aze, alpha-Me-Aze, ACI, and 3Me2-Aze.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein
m is 0;
P1 is:
P2 is C(O)NH2 or C(O)OH;
R1 is an selected from the group consisting of an amino acid side chain of Trp, 7Aza-Trp, 1Me-Trp, 50H-Trp, 5OMe-Trp, 7MeO-Trp, 7Me-Trp, 5F-Trp, 7Cl-Trp, alpha-Me-Trp, and NMe-Trp;
R2 is selected from the group consisting of an amino acid side chain of Thr, alpha-Me-Thr, and NMe-Thr;
R3 is selected from the group consisting of an amino acid side chain of D-Ala, Ala, t-Bu-Ala, and NMe-tBuAla;
A1 is
B1 is CH2;
C1 is CH2;
R4 is selected from the group consisting of an amino acid side chain of 3-(4-piperidinyl)-Ala, PipA(acetic), and 3-(1-morpholinyl)-Ala;
R5 is selected from the group consisting of an amino acid side chain of Asn and NMe-Asn;
R6 is selected from the group consisting of an amino acid side chain of Trp, 2Nal and 1Nal;
R7 is
R8 is selected from the group consisting of an amino acid side chain of Asp, NMe-Asp, and alpha-Me-Asp;
R9 is selected from the group consisting of an amino acid side chain of Trp, 7Aza-Trp, 1Me-Trp, 5F-Trp, 5OMe-Trp, alpha-Me-Trp, 7Cl-Trp, 50H-Trp, 7Me-Trp, 7MeO-Trp, and NMe-Trp; and
R10 is selected from the group consisting of an amino acid side chain of Pro, alpha-Me-Pro, trans4Fluoro-Pro, cis4Fluoro-Pro, trans40H-Pro, cis40H-Pro, 5,5-diMe-Pro, trans4NH2-Pro, and cis4NH2-Pro.

### Claim 16 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein
B1 is CH2 or C(CH3)2; and
C1 is CH2 or C(CH3)2.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein Chelator is independently selected from the group consisting of ethylenediamine tetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA), 1,4,7,10-tetra-azacylcododecane-N,N′,N″,N′″-tetraacetic acid (DOTA), 6-((16-((6-Carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)-4-isothiocyanatopicolinic acid (Macropa), Macrodipa, 2,2′,2″,2′″-(1,10-dioxa-4,7,13,16-tetraazacyclooctadecane-4,7,13,16-tetrayl)tetraacetic acid) (Crown), 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-(2-carboxyethyl) (DOTAGA), 1,4,7-Triazacyclononane-N,N′,N″-triacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (TETA), 1,4,7,10,13-pentaazacyclopentadecane-N,N′,N″,N′″,N″″-pentaacetic acid (PEPA), Deferoxamine (DFO), 5,11,16,22-Tetraazahexacosanediamide (DFO*), N,N′-1,4-Butanediylbis[N-[3-[[(1,6-dihydro-1-hydroxy-6-oxo-2-pyridinyl)carbonyl]amino]propyl]-1,6-dihydro-1-hydroxy-6-oxo-2-pyridinecarboxamide] (HOPO), and 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N″,N′″,N″″,N′″″-hexaacetic acid (HEHA).

### Claim 19 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein the cyclic peptide of Formula C is substituted by at least one chelator.

### Claim 20 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein the cyclic peptide of Formula C is selected from

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein the cyclic peptide comprises a radionuclide.

### Claim 23 (depends on 22)

The cyclic peptide of claim 22, or a pharmaceutically acceptable salt thereof, wherein the radionuclide is selected from C-11, N-13, O-15, F-18, P-32, Sc-47, Co-57, Cu-60, Cu-64, Cu-67, Ga-66, Ga-67, Ga-68, Br-76, Br-77, Kr-81m, Rb-82, Y-86, Zr-89, Sr-89, Y-86, Y-90, Sr-92, Tc-99m, Pd-103, Rh-105, Aq-111, In-111, In-115, I-124, I-131, Pr-142, Pm-149, Sm-153, Gd-159, Ho-166, Lu-175, Lu-177, Re-186, Re-188, Ir-194, Pt-199, TI-201, Pb-203, Pb-212, At-211, Bi-212, Bi-213, Ra-223, Ac-225, Ac-227, and Th-227.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A pharmaceutical composition comprising the cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 1)

A method of treating cancer in a subject in need thereof comprising administering to the subject the cyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the cancer is a DLL3-mediated cancer.

### Claim 28 (depends on 26)

The method of claim 26, wherein the cancer is small cell lung cancer, urothelial cancer, melanoma, or squamous cell carcinoma.

### Claim 29 (depends on 26)

The method of claim 26, wherein the cancer is a neuroendocrine neoplasm, melanoma, or primary brain cancer.

### Claim 30 (depends on 29)

The method of claim 29, wherein the neuroendocrine neoplasm is selected from small cell lung cancer (SCLC), medullary thyroid carcinoma (MTC), large cell neuroendocrine cancer (LCNEC), gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), neuroendocrine prostate cancer (NEPC), small cell prostate cancer (SCPC), Merkel cell carcinoma (MCC), neuroendocrine cervical carcinoma, and Grade 3 neuroendocrine tumors (NETs).

### Claim 31

A peptide having binding specificity for DLL3, wherein the peptide binds to one or more amino acids of A81, L83, G106, A85, and R61 of a DLL3 amino acid sequence of SEQ ID NO: 1.

### Claim at position 30

32-50. (canceled)

### Claim 51 (depends on 29)

The method of claim 29, wherein the neuroendocrine neoplasm is extrapulmonary neuroendocrine carcinoma (NEC) of the cervix.

### Claim 52 (depends on 23)

The cyclic peptide of claim 23, wherein the cyclic peptide is radiolabeled with F-18, Ga-68, In-111, Lu-177, or Ac-225, or a pharmaceutically acceptable salt thereof.

### Claim 53 (depends on 1)

The cyclic peptide of claim 1, wherein the cyclic peptide is selected from compounds 94, 153, 249, and 447:

### Claim 54 (depends on 53)

The cyclic peptide of claim 53, wherein compound 94 is radiolabeled with F-18, Ga-68, In-111, Lu-177, or Ac-225, and pharmaceutically acceptable salts and solvates thereof.

### Claim 55 (depends on 53)

The cyclic peptide of claim 53, wherein compound 153 is radiolabeled with F-18, Ga-68, In-111, Lu-177, or Ac-225, and pharmaceutically acceptable salts and solvates thereof.

### Claim 56 (depends on 53)

The cyclic peptide of claim 53, wherein compound 249 is radiolabeled with F-18, Ga-68, In-111, Lu-177, or Ac-225, and pharmaceutically acceptable salts and solvates thereof.

### Claim 57 (depends on 53)

The cyclic peptide of claim 53, wherein compound 447 is radiolabeled with F-18, Ga-68, In-111, Lu-177, or Ac-225, and pharmaceutically acceptable salts and solvates thereof.
